This report was first published by Endpoints News. To see the original version, click here
The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according to a person familiar with the matter.
The agency hopes to announce its pick to lead CBER within the next month or two, said the person, who spoke to Endpoints News on condition of anonymity. CBER oversees biologics and vaccines and is one of two centers at the FDA responsible for reviewing new pharmaceutical products at the agency.
您已阅读32%（568字），剩余68%（1181字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。